Boost Your Portfolio Returns With These 4 Top-Ranked Liquid Stocks

However, it is important to exercise caution. While high liquidity can indicate that a company is efficiently managing its short-term obligations, it may also suggest underutilization of resources. In some cases, companies with excess liquidity may not be deploying their assets effectively, which could limit growth potential.

Hence, one may consider a company’s efficiency level in addition to its liquidity while identifying prospective winners. A balanced assessment of both liquidity and efficiency can help identify truly promising investment opportunities.

Measures to Identify Liquid Stocks

Current Ratio: It measures current assets relative to current liabilities. The ratio gauges a company’s potential to meet short and long-term debt obligations. A current ratio — the working capital ratio — below 1 indicates that the company has more liabilities than assets. A high current ratio does not always suggest that the company is in good financial shape. It may also indicate that the firm failed to utilize its assets significantly. Hence, a range of 1-3 is considered ideal.

Quick Ratio: Unlike the current ratio, the quick ratio — the “acid-test ratio” or “quick assets ratio” — indicates a company’s ability to pay short-term obligations. It considers inventory, excluding current assets, relative to current liabilities. A quick ratio of more than 1 is desirable, like the current ratio.

Cash Ratio: This is the most conservative ratio among the three, considering cash, cash equivalents and invested funds relative to current liabilities. It measures a company’s ability to meet existing debt obligations using the most liquid assets. Though a cash ratio of more than 1 may suggest sound financials, a higher number may indicate inefficiency in cash utilization.

A ratio greater than 1 is always desirable, but it may not always represent a company’s financial condition.

Screening Parameters

To pick the best of the lot, we have added asset utilization — a widely used measure of a company’s efficiency — as one of the screening criteria. Asset utilization is the ratio of total sales in the past 12 months to the last four-quarter average of total assets. Though this ratio varies across industries, companies with a ratio higher than that of their industry can be considered efficient.

We added our proprietary Growth Score to the screen to ensure these liquid and efficient stocks have solid growth potential.

Current Ratio, Quick Ratio, and Cash Ratio between 1 and 3: While liquidity ratios greater than 1 are desirable, significantly high ratios may indicate inefficiency.

Asset utilization is more significant than the industry average: A higher asset utilization than the industry average indicates a company’s efficiency.

Zacks Rank equal to #1 (Strong Buy): Only Strong Buy-rated stocks can get through. You can see the complete list of today’s Zacks #1 Rank stocks here.

Growth Score less than or equal to B: Back-tested results show that stocks with a Growth Score of A or B handily beat other stocks when combined with a Zacks Rank #1 or 2 (Buy).

These criteria have narrowed the universe of more than 7,700 stocks to only eight.

Here are four of the eight stocks that qualified the screen:

Invesco operates as an independent investment manager. As of June 30, 2026, assets under management (AUM) were $2.5 trillion.

Second-quarter 2026 adjusted net revenues were $1.33 billion, rising 20.3% year over year. AUM of $2.5 trillion was underpinned by $45 billion in net long-term inflows, marking the 12th consecutive quarter of positive flows.  The growth was broad-based, with QQQ, ETFs and Index, China JV and Private Markets emerging as major drivers.

In the second quarter, IVZ expanded its BulletShares lineup with seven new fund launches in the United States. It also established five ETFs in EMEA, including two new active funds.

The Zacks Consensus Estimate for IVZ’s 2026 earnings is pinned at $2.80 per share, down 1 cent in the past seven days. The company has a Growth Score of B and a trailing four-quarter earnings surprise of 12.45%, on average.

HubSpot is an AI-driven customer relationship management (CRM) platform. The integration of advanced AI tools and state-of-the-art features, such as AI assistance, AI agents, AI insights, and ChatSpot, across its entire product suite and customer platform is delivering greater value to customers. HubSpot now has a total customer count of approximately 306,000.

The software-as-a-service vendor’s second-quarter 2026 revenues improved to $911.7 million, up 17% at cc from the year-ago quarter. Subscription revenues increased 20% year over year to $894 million. However, the company had a slower start to the quarter in April with weaker-than-expected customer additions (7,000 vs. ~9,000–10,000 target), reflecting lower conversion rates and rising buyer caution.

Despite these near-term headwinds, long-term prospects remain healthy as AI adoption accelerates meaningfully. Upmarket wins and multi-hub growth are other tailwinds. Full-year 2026 revenues are projected at $3.678–$3.686 billion with an operating margin of 21%.

The Zacks Consensus Estimate for HUBS’ 2026 earnings stands at $13.12 per share, up 1 cent in the past seven days. The company has a Growth Score of A and a trailing four-quarter earnings surprise of 6.13%, on average.

Hinge Health is a digital musculoskeletal (MSK) care platform that combines AI-driven software, personalized therapy, remote coaching, and motion tracking to offer scalable care for large employers and health plans, reducing physical therapy costs.

Second-quarter 2026 revenues came in at  $213 million, up 53% year over year. Last 12-month billings growth of 52% reflected sustained demand momentum. While its core MSK business remains the foundation, the company is expanding into new avenues such as migraine care and gastrointestinal health. On the earnings call, management highlighted that the migraine care business was scaling fast, with more than 450 clients and 5 million covered lives already.  The recent acquisition of Cylinder Health broadens its total addressable market in the gastrointestinal space. 

Management raised full-year guidance following a strong second-quarter performance. For 2026, revenues are now expected in the range of $856-$860 million (implying 46% growth at midpoint), alongside operating income of $236-$244 million.

The Zacks Consensus Estimate for HNGE’s 2026 earnings stands at $2.52 per share, unchanged in the past seven days. The company has a Growth Score of A and a trailing four-quarter earnings surprise of 18.43%, on average.

Progyny is a healthcare company specializing in women's health and family building solutions.

Second-quarter 2026 revenues were up 5.3% to $350.5 million. The top-line expansion was supported by a higher number of clients and covered lives but was partly offset by the impact of a large client who did not renew for 2025. This client contributed $17.2 million to revenues in the second quarter of 2025.

Fertility services remain Progyny’s core growth engine, with revenues jumping 7.6% year over year to $230.2 million. As of June 30, 2026, PGNY had 604 fertility and family-building clients. For 2026, Progyny expects revenues in the range of $1.36 billion to $1.385 billion, implying 5.5%–7.5% reported growth. The third quarter is expected to see slightly more pronounced seasonal softness related to member activity.

The Zacks Consensus Estimate for PGYNY’s 2026 earnings stands at $2.04 per share, unchanged in the past seven days. The company has a Growth Score of A and a trailing four-quarter earnings surprise of 15.8%, on average.

Why Haven't You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can access their live picks without cost or obligation.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research